A Cefixime anhydrous, (E)- CEP of the European Pharmacopoeia monograph is often referred to as a Cefixime anhydrous, (E)- Certificate of Suitability (COS). The purpose of a Cefixime anhydrous, (E)- CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefixime anhydrous, (E)- EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefixime anhydrous, (E)- to their clients by showing that a Cefixime anhydrous, (E)- CEP has been issued for it. The manufacturer submits a Cefixime anhydrous, (E)- CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefixime anhydrous, (E)- CEP holder for the record. Additionally, the data presented in the Cefixime anhydrous, (E)- CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefixime anhydrous, (E)- DMF.
A Cefixime anhydrous, (E)- CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefixime anhydrous, (E)- CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefixime anhydrous, (E)- suppliers with CEP (COS) on PharmaCompass.